Diabetic Retinopathy Industry

Summary:

• The global diabetic retinopathy market size reached US$ 8.1 Billion in 2023.
• The market is expected to reach US$ 13.0 Billion by 2032, exhibiting a growth rate (CAGR) of 5.2% during 2024-2032.
• North America leads the market, accounting for the largest diabetic retinopathy market size.
• Non-proliferative retinopathy accounts for the majority of the market share in the type segment because it can be more frequently diagnosed and treated than the more severe proliferative form.
• Anti-VEGF drugs holds the largest share in the diabetic retinopathy industry.
• Hospitals and pharmacies remain a dominant segment in the market because they are the initial points of care (POC) for the administration of treatments and management of diabetic retinopathy.
• The increasing adoption of telemedicine and remote monitoring tools is enhancing access to diabetic retinopathy screenings in underserved and rural areas, driving market growth.
• The global diabetic retinopathy market is experiencing substantial growth, primarily fueled by the rising prevalence of diabetes and the expanding geriatric population.
• Rising healthcare expenditure and government initiatives aimed at improving diabetic care infrastructure are further boosting the availability of advanced treatments for diabetic retinopathy, accelerating market demand.

Industry Trends and Drivers:

Rising prevalence of diabetes: As the global population continues to age and obesity rates increase, more individuals are developing type 1 and type 2 diabetes, which are key risk factors for diabetic retinopathy. Diabetic retinopathy occurs when chronic high blood sugar levels cause damage to the blood vessels in the retina, potentially leading to blindness if left untreated. According to global health organizations, the number of people with diabetes is expected to rise significantly in the coming years, particularly in developing countries where urbanization and lifestyle changes are contributing to higher rates of the disease. As the number of diabetic patients grows, so does the need for effective management and treatment of complications such as diabetic retinopathy, strengthening the market demand.

Advancements in diagnostic technologies: Early detection is critical for preventing vision loss caused by diabetic retinopathy, and innovations in diagnostic tools are improving the accuracy and accessibility of screening methods. For example, the development of non-invasive imaging techniques, such as optical coherence tomography (OCT) and fundus photography, has revolutionized the way diabetic retinopathy is diagnosed. These technologies allow for detailed visualization of retinal structures, enabling early identification of disease progression. Furthermore, artificial intelligence (AI) and machine learning algorithms are being integrated into diagnostic systems to automate the detection of diabetic retinopathy from retinal images, increasing the efficiency and accuracy of screening processes and thereby aiding the market growth.

Increasing awareness of the importance of early diagnosis and treatment: Public health initiatives, medical campaigns, and educational programs are raising awareness about the risks of untreated diabetic retinopathy and the benefits of regular eye examinations for diabetic patients. Healthcare providers are emphasizing the importance of annual eye screenings to detect retinopathy before symptoms become severe, particularly among high-risk populations. Additionally, the availability of effective treatments such as anti-vascular endothelial growth factor (VEGF) injections, laser therapy, and vitrectomy surgery is encouraging more patients to seek timely interventions. As awareness about diabetic retinopathy and the available treatments grows, more patients are being diagnosed and treated at earlier stages, further contributing to the demand for related medical products and services.

Request for a sample copy of this report: https://www.imarcgroup.com/diabetic-retinopathy-market/requestsample

Diabetic Retinopathy Market Report Segmentation:

Breakup By Type:

• Proliferative Diabetic Retinopathy
• Non-proliferative Retinopathy

Non-proliferative retinopathy accounts for the majority of shares, as is the early stage of diabetic retinopathy, it is making it more commonly diagnosed and treated than the more severe proliferative form.

Breakup By Treatment Type:

• Anti VEGF Drugs
• Steroid Implants
• Laser Surgeries
• Vitrectomy

Anti-VEGF drugs dominate the market due to their effectiveness in halting disease progression and preventing vision loss in patients with diabetic retinopathy.

Breakup By End User:

• Hospitals and Pharmacies
• Eye Clinics
• Ambulatory Surgical Centres (ASCs)
• Others

Hospitals and pharmacies represent the majority of shares as they are the primary points of care (POC) for the administration of treatments and management of diabetic retinopathy, offering comprehensive services.

Breakup By Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America holds the leading position due to the high prevalence of diabetes, advanced healthcare infrastructure, and strong adoption of cutting-edge diabetic retinopathy treatments.

Top Diabetic Retinopathy Market Leaders:

The diabetic retinopathy market research report outlines a detailed analysis of the competitive landscape, offering in-depth profiles of major companies.

Some of the key players in the market are:

• Alimera Sciences
• Allergan PLC
• Ampio Pharmaceuticals
• Bayer Healthcare
• BCN Peptides
• Genentech
• Kowa Group
• Novartis AG
• Regeneron Pharmaceuticals Inc. and Sirnaomics Inc.

Browse full report with TOC List of Figures: https://www.imarcgroup.com/request?type=reportid=1932flag=C

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.